A method for improving primary memory or learning in a mammal comprising administering a 5-hydroxytryptamine receptor agonist which is selective for the 5-hydroxytryptamine-1A receptor subtype, or a pharmaceutically acceptable salt thereof.
There are disclosed compositions for oral administration of a novel pharmaceutical composition, which includes xanthine-based stimulants, various neurotransmitter precursors, minerals, nootropic herbs, and amino acids capable of augmenting the preparation. Also, embodied in these compositions are specific cerebral vasodilators and cognition enhancing neurosteroids.
5470853 - 6-substituted-hexahydrobenz [CD] indoles - Owned by Eli Lilly and Company (Indianapolis, IN) [*] Notice:The portion of the term of this patent subsequent to April 12, 2011 has been disclaimed.
The present invention provides 4-amino-6-substituted-hexahydrobenz[cd]indoles which are useful in treating disease states which can be benefited by an alteration of 5-HT.sub.1.sbsb.A receptors.
Gepirone compositions having extended release properties contain a gepirone salt, a cellulosic polymer matrix and suitable quantities of pharmaceutical excipients. Dosage forms based thereon require 18 to 24 hours for release of 90 to 95% of gepirone.
